⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.

CIPLA - Technical Analysis with Chart Patterns & Indicators

← Back to List

⭐ Rating: 4

Last Updated Time : 19 Sept 26, 03:33 pm

Key Parameters

⭐ Technical Rating: 4.0

RSI48.2
MACD-16.9
DMA 501,409 ₹
DMA 2001,409 ₹
High / Low1,673 ₹
Low price1,166 ₹
High price1,673 ₹
52w Index40.6 %
Show all parameters (20 more)
Stock CodeCIPLA
Market Cap1,11,121 Cr.
Current Price1,371 ₹
Stock P/E33.9
Book Value423 ₹
Dividend Yield0.95 %
ROCE13.7 %
ROE10.4 %
Face Value2.00 ₹
Chg in FII Hold-2.35 %
Chg in DII Hold2.64 %
PAT Qtr862 Cr.
PAT Prev Qtr385 Cr.
Volume13,98,150
Avg Vol 1Wk10,85,364
PEG Ratio3.24
Debt to equity0.00
Qtr Profit Var-33.8 %
EPS38.1 ₹
Industry PE34.8

🧾 Chart Verdict

Optimal entry zone could be between 1,350 ₹ – 1,375 ₹ if a short-term bounce occurs, utilizing the recent high as support. An exit strategy would be to set a stop-loss order around 1,320 ₹ - 1,300 ₹ to protect profits during potential downside movement given the negative MACD and RSI signals. Overall, the stock maintains a bullish lean based on revenue growth and USFDA approvals, but requires careful monitoring for signs of weakening momentum or increased selling pressure.

✅ Positive

The price is currently trading near its recent high of 1,673 ₹, indicating strong support and potential upward momentum. Volume remains elevated compared to the one-week average, suggesting sustained interest in the stock.

⚠️ Limitation

Despite the positive momentum, the RSI reading of 48.2 suggests that the stock hasn’t yet entered overbought territory, but it also doesn't signal extreme bullishness. The MACD is negative and relatively weak, hinting at potential resistance ahead, and a break below current levels could trigger further downside pressure.

📉 Company Negative News

Recent news reports indicate a -2.35% decrease in FII holding and a 2.64% increase in DII holdings, suggesting reduced institutional investor confidence, but overall positive FY26 revenue growth. The scanx.trade article regarding the GST inspection concluded with no material impact, offering reassurance after initial concern.

📈 Company Positive News

Cipla achieved record revenue of ₹28,000 crore in FY26, significantly exceeding previous figures. Furthermore, the USFDA approval for generic Ventolin inhaler is positive news and should drive further growth.

🏭 Industry

The pharmaceutical sector is currently characterized by moderate growth driven by increasing healthcare spending and generic drug demand. The industry PE of 34.8 suggests that Cipla’s valuation is in line with its peers, reflecting reasonable expectations for future earnings growth within the broader market trends.

Choose Technical Analysis or Fundamental Analysis above to load it.

How CIPLA Rates Across All Strategies

★ 4.2
Entry Price: 1,371 ₹.
★ 4.2
Buy at 1365 ₹ with a stop-loss order set at 1340 ₹.
★ 3.8
An ideal entry price zone would be between 1,280 ₹ and 1,350 ₹, targe…
Technical
★ 4.0
You're viewing this analysis below.
★ 3.2
We recommend a potential entry zone between 1,280 ₹ - 1,340 ₹ based o…

NIFTY 50 · Technical

NEXT 50 · Technical

MIDCAP · Technical

SMALLCAP · Technical